ASCO 25:安进Imdelltra使肺癌死亡风险较化疗降低40%

药事纵横
Jun 05, 2025

在本周一举行的美国临床肿瘤学会(ASCO)年会上,安进公司展示了其针对DLL3的T细胞结合剂Imdelltra(tarlatamab-dlle)的Ⅲ期临床数据,同时该研究也发表于《新英格兰医学杂志》(NEJM)。研究结果显示,与标准化疗方案相比,Imdelltra能够降低复发性小细胞肺癌(SCLC)患者40%的死亡风险,兑现了其此前的治疗承诺。去年,该药物基于肿瘤反应率获得了美国食品药品监督管理局...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10